IMPORTANCE: Breast cancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breast cancer morbidity and mortality. OBJECTIVE: To update the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer. PROCESS: The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms. EVIDENCE SYNTHESIS: Screening mammography in women aged 40 to 69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening for women 70 years and older who are in good health. Estimates of the cumulative lifetime risk of false-positive examination results are greater if screening begins at younger ages because of the greater number of mammograms, as well as the higher recall rate in younger women. The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs biennially. Evidence does not support routine clinical breast examination as a screening method for women at average risk. RECOMMENDATIONS: The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). Women aged 45 to 54 years should be screened annually (qualified recommendation). Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation). CONCLUSIONS AND RELEVANCE: These updated ACS guidelines provide evidence-based recommendations for breast cancer screening for women at average risk of breast cancer. These recommendations should be considered by physicians and women in discussions about breast cancer screening.
IMPORTANCE: Breast cancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breast cancer morbidity and mortality. OBJECTIVE: To update the American Cancer Society (ACS) 2003 breast cancer screening guideline for women at average risk for breast cancer. PROCESS: The ACS commissioned a systematic evidence review of the breast cancer screening literature to inform the update and a supplemental analysis of mammography registry data to address questions related to the screening interval. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms. EVIDENCE SYNTHESIS: Screening mammography in women aged 40 to 69 years is associated with a reduction in breast cancer deaths across a range of study designs, and inferential evidence supports breast cancer screening for women 70 years and older who are in good health. Estimates of the cumulative lifetime risk of false-positive examination results are greater if screening begins at younger ages because of the greater number of mammograms, as well as the higher recall rate in younger women. The quality of the evidence for overdiagnosis is not sufficient to estimate a lifetime risk with confidence. Analysis examining the screening interval demonstrates more favorable tumor characteristics when premenopausal women are screened annually vs biennially. Evidence does not support routine clinical breast examination as a screening method for women at average risk. RECOMMENDATIONS: The ACS recommends that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years (strong recommendation). Women aged 45 to 54 years should be screened annually (qualified recommendation). Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation). Women should have the opportunity to begin annual screening between the ages of 40 and 44 years (qualified recommendation). Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation). The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age (qualified recommendation). CONCLUSIONS AND RELEVANCE: These updated ACS guidelines provide evidence-based recommendations for breast cancer screening for women at average risk of breast cancer. These recommendations should be considered by physicians and women in discussions about breast cancer screening.
Authors: Suzie J Otto; Jacques Fracheboud; Caspar W N Looman; Mireille J M Broeders; Rob Boer; Jan H C L Hendriks; André L M Verbeek; Harry J de Koning Journal: Lancet Date: 2003-04-26 Impact factor: 79.321
Authors: Robert A Smith; Debbie Saslow; Kimberly Andrews Sawyer; Wylie Burke; Mary E Costanza; W Phil Evans; Roger S Foster; Edward Hendrick; Harmon J Eyre; Steven Sener Journal: CA Cancer J Clin Date: 2003 May-Jun Impact factor: 508.702
Authors: James Michaelson; Sameer Satija; Richard Moore; Griffin Weber; Elkan Halpern; Andrew Garland; Dhruv Puri; Daniel B Kopans Journal: Cancer Date: 2002-01-01 Impact factor: 6.860
Authors: James S Michaelson; Sameer Satija; Daniel Kopans; Richard Moore; Melvin Silverstein; Arthur Comegno; Kevin Hughes; Alphonse Taghian; Simon Powell; Barbara Smith Journal: Cancer Date: 2003-11-15 Impact factor: 6.860
Authors: Lori L DuBenske; Sarina B Schrager; Mary E Hitchcock; Amanda K Kane; Terry A Little; Helene E McDowell; Elizabeth S Burnside Journal: J Gen Intern Med Date: 2018-07-20 Impact factor: 5.128
Authors: Elisabeth F Beaber; Anna N A Tosteson; Jennifer S Haas; Tracy Onega; Brian L Sprague; Donald L Weaver; Anne Marie McCarthy; Chyke A Doubeni; Virginia P Quinn; Celette Sugg Skinner; Ann G Zauber; William E Barlow Journal: Breast Cancer Res Treat Date: 2016-09-24 Impact factor: 4.872
Authors: Jeroen J van den Broek; Nicolien T van Ravesteyn; Jeanne S Mandelblatt; Hui Huang; Mehmet Ali Ergun; Elizabeth S Burnside; Cong Xu; Yisheng Li; Oguzhan Alagoz; Sandra J Lee; Natasha K Stout; Juhee Song; Amy Trentham-Dietz; Sylvia K Plevritis; Sue M Moss; Harry J de Koning Journal: Med Decis Making Date: 2018-04 Impact factor: 2.583
Authors: Lars J Grimm; David Y Johnson; Karen S Johnson; Jay A Baker; Mary Scott Soo; E Shelley Hwang; Sujata V Ghate Journal: Eur Radiol Date: 2016-10-17 Impact factor: 5.315
Authors: Amanda M Pugh; Courtney M Giannini; Susan M Pinney; Dennis J Hanseman; Elizabeth A Shaughnessy; Jaime D Lewis Journal: Am J Surg Date: 2018-09-20 Impact factor: 2.565
Authors: Elisabeth F Beaber; Brian L Sprague; Anna N A Tosteson; Jennifer S Haas; Tracy Onega; Marilyn M Schapira; Anne Marie McCarthy; Christopher I Li; Sally D Herschorn; Constance D Lehman; Karen J Wernli; William E Barlow Journal: J Womens Health (Larchmt) Date: 2018-11-27 Impact factor: 2.681